On December 12, Vietnam’s Tam Anh General Hospital System announced the VISTA-1 study on RBS2418, an innovative oral immunotherapy for advanced colorectal cancer resistant to current treatments, marking the first research site outside the U.S. for this groundbreaking drug candidate.
The launching ceremony featured representatives from Vietnam’s Ministry of Health, the Ministry of Foreign Affairs, and the U.S. Centers for Disease Control and Prevention (CDC).
Approved by the Ministry of Health earlier this month, VISTA-1 is the first Phase 2A clinical trial of its kind in Vietnam, highlighting a significant advancement in the nation’s role in global cancer research. Initially targeting 150 patients in the U.S. and Vietnam, the study will expand to three additional hospitals in the country.
Dr. Nguyen Ngo Quang, director of the Department of Science, Technology, and Training at the Ministry of Health, emphasized the unique nature of this trial, which involves collaboration between Vietnamese and American researchers in developing the study protocol and establishing internationally accredited laboratory systems. (Dan Tri, Bao Chinh Phu, Tuoi Tre, Dai Bieu Nhan Dan)